Free tool
FAERS Monitor: Yesafili
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761274 or its brand name (Yesafili, Aflibercept-Jbvf). Reports on generic versions are filed under their own applications.
Reports
16
Serious
15
94% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye haemorrhage4
- visual impairment3
- drug ineffective2
- eye pain2
- lacrimation increased2
- subretinal fluid2
- vision blurred2
- vitreous floaters2
- blindness unilateral1
- eye disorder1
- eye swelling1
- fall1
- glaucoma1
- headache1
- inappropriate schedule of product administration1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| subretinal fluid | 2 | 2412.3 | 658.9 | 2,706 |
| eye haemorrhageSignal | 4 | 394.2 | 168.7 | 1,201 |
| vitreous floaters | 2 | 267.6 | 73.2 | 298 |
| blindness unilateral | 1 | 93.2 | 14.0 | 22 |
| lacrimation increased | 2 | 87.0 | 23.8 | 95 |
| glaucoma | 1 | 68.3 | 10.2 | 16 |
| eye pain | 2 | 46.6 | 12.7 | 50 |
| eye disorder | 1 | 40.0 | 6.0 | 9 |
| eye swelling | 1 | 35.3 | 5.3 | 8 |
| visual impairmentSignal | 3 | 31.8 | 11.5 | 62 |
| vision blurred | 2 | 19.1 | 5.2 | 19 |
| inappropriate schedule of product administration | 1 | 7.3 | 1.1 | 1 |
| fall | 1 | 3.9 | 0.6 | 0 |
| headache | 1 | 2.1 | 0.3 | 0 |
| drug ineffective | 2 | 2.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.